@FierceBiotech: Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16. Article | Follow @FierceBiotech
@JohnCFierce: Sounds right. Deal fest in San Francisco while $IBB takes an ugly 5% drop. Bon chance to you stock guys; off to a rough start at #JPM16. | Follow @JohnCFierce
@DamianFierce: warm memories from last year's jp morgan when, after a full day of meetings, I found this on the back of my collar. More | Follow @DamianFierce
> Gilead Sciences ($GILD) filed its investigational tenofovir alafenamide for FDA approval in hepatitis B. News
> Moderna Therapeutics secured a $20 million grant from the Bill & Melinda Gates Foundation to advance its HIV candidate. More
> Intellia Therapeutics launched a new division focused on gene editing technology. Release
Medical Device News
@FierceMedDev: Medtronic to build Chinese facility for the manufacture of advanced diabetes devices. Article | Follow @FierceMedDev
@EmilyWFierce: Congressional reps urge the NIH to 'march in' on rising drug prices. FiercePharma story | Follow @EmilyWFierce
> JPM: Illumina's genomic ambitions fueled by new sequencing tools and technology. Story
> Boston Scientific launches disposable digital urinary tract endoscope. Article
> JPM: Medtronic aims for double-digit returns with more buybacks, faster dividends and debt paydown. More
Pharma News
@FiercePharma: BioAtla scores $45M investment for CAB development. FiercePharmaAsia story | Follow @FiercePharma
@CarlyHFierce: ICYMI: U.K. investor Woodford calls again for breakup of 'complicated' GSK. Article | Follow @CarlyHFierce
> Celgene ends horse race for Hugin's successor, tapping Mark Alles as new CEO. Story
> Now focused on integrating Allergan generics, Teva eyes 'much larger' specialty buy in 2017. Article
Drug Delivery News
> Australia's Elastagen receives $9M to deploy its human protein formulation to aesthetics and tissue repair. News
> Back-of-the-eye delivery outfit Clearside files for $58 million IPO. Story
> One microcapsule could combine two drug ingredients when triggered at tumor site. More
> JPM: Halozyme to focus on its internal pancreatic cancer candidate in 2016. Report
> Xeris raises $41M to develop diabetes injection pen for glucagon administration. Article
Pharma Manufacturing News
> BD exiting sterile injectables biz, selling plant and portfolio to Fresenius Kabi. More
> Consent decree issued against recalcitrant compounder. Item
> Perrigo, already recalling Zyrtec copy, now recalling knockoff of Mucinex for children. Report
> FDA warning letter tells Cadila to resolve problems with warfarin production. Story
> European regulators sanction Chinese company for plant flaws. Article
Pharma Asia News
> BioAtla scores $45M investment for CAB development. More
> Japan's Takeda and enGene in GI therapy development pact. Item
> Glenmark's BEAT platform helps develop new cancer molecule. Article
> Amgen sues South Korea's Samsung Bioepis over Enbrel biosimilar. Report
> Singapore's NRF unveils 5-year, $13B research budget. Story